A carregar...
Two-Year US Pharmacovigilance Report on Brodalumab
INTRODUCTION: Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. In the U...
Na minha lista:
| Publicado no: | Dermatol Ther (Heidelb) |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Healthcare
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7859129/ https://ncbi.nlm.nih.gov/pubmed/33337520 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-020-00472-x |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|